– Christine
Gorjanc resumes role as Chair of the Audit Committee of the
Board of Directors for Invitae –
SAN
FRANCISCO, Aug. 14, 2023 /PRNewswire/ -- Invitae
(NYSE: NVTA), a leading medical genetics company, today announced
that Robert Dickey has been named
its interim chief financial officer (CFO), effective immediately.
Christine Gorjanc, who had assumed
the interim CFO role in June 2023,
will transition back to her prior role as the Company's Chair of
the Audit Committee of the Board of Directors and member of the
Compensation Committee of the Board of Directors, effective
immediately. Ms. Gorjanc will work closely with Mr. Dickey and the
executive leadership team to ensure a smooth transition. She will
also continue to assist the Company with the search for its
permanent CFO.
"I'm grateful for Christine's willingness to immediately step in
as interim CFO, bridging our short term needs and helping us select
the right candidate for the near term transition while continuing
to assist with our long term needs by identifying candidates for
the permanent CFO role," said Ken
Knight, president and chief executive officer of Invitae.
"Robert Dickey brings extensive
private and public company financial leadership experience to the
role of interim CFO, and he has consistently demonstrated an
ability to manage successfully in similar interim finance and
permanent board level roles with life science companies. We are
pleased to have identified an executive with his track record and
financial acumen."
Mr. Dickey is an exceptional finance executive with over 25
years experience as a CFO as well as other C-level and board
positions at both private and publicly traded life sciences and
medical device companies. Mr. Dickey is experienced in all stages
of the corporate lifecycle, including start-up and fundraising, the
IPO process, high growth and turnarounds as well as interactions
with directors, shareholders and the investment community. Earlier
in his career, Mr. Dickey spent 18 years in investment banking,
mostly at Lehman Brothers, with a background divided between
M&A and capital markets transactions. As a part-time or interim
CFO, Mr. Dickey has consulted with more than 10 companies in the
life sciences space. He currently serves as a member of the Board
of Directors at AngioGenex, SFA Therapeutics and GSNO Therapeutics.
Mr. Dickey holds an MBA from The Wharton School, University of Pennsylvania, and an AB from
Princeton University.
"I was honored to step in and lend my finance and accounting
expertise while the executive leadership team identified a longer
term interim CFO," said Christine
Gorjanc, Chair of the Audit Committee of the Board of
Directors for Invitae. "With Rob's skills and experience, I am
confident that Invitae's finance team will grow even stronger under
his leadership."
About Invitae
Invitae (NYSE: NVTA) is a leading
medical genetics company trusted by millions of patients and their
providers to deliver timely genetic information using digital
technology. We aim to provide accurate and actionable answers to
strengthen medical decision-making for individuals and their
families. Invitae's genetics experts apply a rigorous approach to
data and research, serving as the foundation of their mission to
bring comprehensive genetic information into mainstream medicine to
improve healthcare for billions of people.
To learn more, visit invitae.com and follow for updates on
Twitter, Instagram, Facebook and
LinkedIn @Invitae.
Safe Harbor Statement
This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements
relating to Ms. Gorjanc's future assistance and service with the
Company; Mr. Dickey's future assistance and service as interim CFO;
and the Company's efforts to hire a permanent CFO. Forward-looking
statements are subject to risks and uncertainties that could cause
actual results to differ materially, and reported results should
not be considered as an indication of future performance. These
risks and uncertainties include, but are not limited to: the
company's ability to grow its business in a cost-efficient manner;
the company's history of losses; the company's ability to maintain
important customer relationships; the company's ability to compete;
the company's failure to manage growth effectively; the company's
need to scale its infrastructure in advance of demand for its tests
and to increase demand for its tests; risks associated with
litigation; the company's ability to use rapidly changing genetic
data to interpret test results accurately and consistently;
security breaches, loss of data and other disruptions; laws and
regulations applicable to the company's business; and the other
risks set forth in the company's filings with the Securities and
Exchange Commission, including the risks set forth in the company's
Quarterly Report on Form 10-Q for the quarter ended June 30, 2023. These forward-looking statements
speak only as of the date hereof, and Invitae Corporation disclaims
any obligation to update these forward-looking statements.
Invitae Contacts:
Investor Relations
Hoki
Luk
ir@invitae.com
Public Relations
Amy
Hadsock
pr@invitae.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/invitae-announces-selection-of-finance-executive-robert-dickey-as-interim-cfo-301900104.html
SOURCE Invitae Corporation